Browse by Research Project Code

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0

Gök, C. , Main, A., Gao, X., Kerekes, Z., Plain, F., Kuo, C.-W., Robertson, A. D., Fraser, N. J. and Fuller, W. (2021) Insights into the molecular basis of the palmitoylation and depalmitoylation of NCX1. Cell Calcium, 97, 102408. (doi: 10.1016/j.ceca.2021.102408)

Docherty, K. F. et al. (2021) The effect of neprilysin inhibition on left ventricular remodeling in patients with asymptomatic left ventricular systolic dysfunction late after myocardial infarction. Circulation, (doi: 10.1161/CIRCULATIONAHA.121.054892) (PMID:33983794) (Early Online Publication)

Heggie, R. et al. (2021) Stratified medicine using invasive coronary function testing in angina: a cost-effectiveness analysis of the British Heart Foundation CorMicA trial. International Journal of Cardiology, (Accepted for Publication)

Mary, S. , Small, H., Herse, F., Carrick, E., Flynn, A., Mullen, W. , Dechend, R. and Delles, C. (2021) Pre-existing hypertension and pregnancy induced hypertension reveal molecular differences in placental proteome in rodents. Physiological Genomics, (Accepted for Publication)

Rossitto, G. et al. (2021) High sodium intake, glomerular hyperfiltration and protein catabolism in patients with essential hypertension. Cardiovascular Research, 117(5), pp. 1372-1381. (doi: 10.1093/cvr/cvaa205) (PMID:33053160)

Connelly, P. J. , Azizi, Z., Alipour, P., Delles, C. , Pilote, L. and Raparelli, V. (2021) The importance of gender to understand sex differences in cardiovascular disease. Canadian Journal of Cardiology, 37(5), pp. 699-710. (doi: 10.1016/j.cjca.2021.02.005) (PMID:33592281)

Shen, L. et al. (2021) Incidence and outcomes of pneumonia in patients with heart failure. Journal of the American College of Cardiology, 77(16), pp. 1961-1973. (doi: 10.1016/j.jacc.2021.03.001) (PMID:33888245)

Sattar, N. and Forouhi, N. G. (2021) More evidence for 5-a-day for fruit and vegetables and a greater need for translating dietary research evidence to practice. Circulation, 143(17), pp. 1655-1658. (doi: 10.1161/CIRCULATIONAHA.121.053293) (PMID:33900834)

He, T. et al. (2021) Urinary peptides in heart failure: a link to molecular pathophysiology. European Journal of Heart Failure, (doi: 10.1002/ejhf.2195) (PMID:33881206) (Early Online Publication)

Jhund, P. S. et al. (2021) Dapagliflozin and recurrent heart failure hospitalizations in heart failure with reduced ejection fraction: an analysis of DAPA-HF. Circulation, (doi: 10.1161/CIRCULATIONAHA.121.053659) (PMID:33832352) (Early Online Publication)

Touyz, R. M. and Schiffrin, E. L. (2021) A compendium on hypertension: new advances and future impact. Circulation Research, 128(7), pp. 803-807. (doi: 10.1161/CIRCRESAHA.121.319181) (PMID:33793329)

Griendling, K. K., Camargo, L. L., Rios, F. , Alves-Lopes, R., Montezano, A. C. and Touyz, R. M. (2021) Oxidative stress and hypertension. Circulation Research, 128(7), pp. 993-1020. (doi: 10.1161/CIRCRESAHA.121.318063) (PMID:33793335)

Cleland, J. G.F. et al. (2021) The struggle towards a universal definition of heart failure—how to proceed? European Heart Journal, (doi: 10.1093/eurheartj/ehab082) (PMID:33791787) (Early Online Publication)

van Dorst, D. C.H., Dobbin, S. J.H. , Neves, K. B. , Herrmann, J., Herrmann, S. M., Versmissen, J., Mathijssen, R. H.J., Danser, A.H. J. and Lang, N. N. (2021) Hypertension and prohypertensive antineoplastic therapies in cancer patients. Circulation Research, 128(7), pp. 1040-1061. (doi: 10.1161/CIRCRESAHA.121.318051) (PMID:33793337) (PMCID:PMC8011349)

Scott, K., Morgan, H. L., Delles, C. , Fisher, S., Graham, D. and McBride, M. W. (2021) Distinct uterine artery gene expression profiles during early gestation in the stroke-prone spontaneously hypertensive rat. Physiological Genomics, 53(4), pp. 160-171. (doi: 10.1152/physiolgenomics.00159.2020) (PMID:33719581)

Mooney, L., Goodyear, C. S. , Chandra, T., Kirshner, K., Copland, M. , Petrie, M. C. and Lang, N. N. (2021) Clonal haematopoiesis of indeterminate potential: intersections between inflammation, vascular disease and heart failure. Clinical Science, 135(7), pp. 991-1007. (doi: 10.1042/CS20200306) (PMID:33861346)

Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin in men and women with heart failure with reduced ejection fraction: results from the DAPA-HF trial. JAMA Cardiology, (doi: 10.1001/jamacardio.2021.0379) (Early Online Publication)

Graham, F. J., Pellicori, P. , Ford, I. , Petrie, M. C. , Kalra, P. R. and Cleland, J. G.F. (2021) Intravenous iron for heart failure with evidence of iron deficiency: a meta-analysis of randomised trials. Clinical Research in Cardiology, (doi: 10.1007/s00392-021-01837-8) (PMID:33755777) (Early Online Publication)

Halliday, B. P. et al. (2021) Heart rate as a marker of relapse during withdrawal of therapy in recovered dilated cardiomyopathy. JACC: Heart Failure, (Accepted for Publication)

Lee, M. M.Y. , Ghouri, N. , McGuire, D. K., Rutter, M. K. and Sattar, N. (2021) Meta-analyses of results from randomized outcome trials comparing cardiovascular effects of SGLT2i and GLP-1RA in Asian vs. White patients with and without type 2 diabetes. Diabetes Care, (doi: 10.2337/dc20-3007) (PMID:33707305) (Early Online Publication)

Boder, P., Mary, S., Mark, P. B. , Leiper, J. , Dominiczak, A. F. , Padmanabhan, S. , Rampold, L. and Delles, C. (2021) Mechanistic interactions of uromodulin with the thick ascending limb: perspectives in physiology and hypertension. Journal of Hypertension, (Accepted for Publication)

Sigfrid, L. et al. (2021) What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? A harmonised, global longitudinal observational study protocol. BMJ Open, 11(3), e043887. (doi: 10.1136/bmjopen-2020-043887) (PMID:33692181) (PMCID:PMC7948153)

Crouch, S. H., Botha-Le Roux, S., Delles, C. , Graham, L. A. and Schutte, A. E. (2021) Inflammation and salt in young adults: the African-PREDICT study. European Journal of Nutrition, 60(2), pp. 873-882. (doi: 10.1007/s00394-020-02292-3) (PMID:32494865) (PMCID:PMC7900065)

Sykes, R. A. , Mohamed, M. O., Kwok, C. S., Mamas, M. A. and Berry, C. (2021) Percutaneous coronary intervention and 30-day unplanned readmission with chest pain in the United States (nationwide readmissions database). Clinical Cardiology, 44(3), pp. 291-306. (doi: 10.1002/clc.23543) (PMID:33590937) (PMCID:PMC7943906)

Briscoe, M., Sykes, R. , Krystofiak, T., Peck, O., Mangion, K. and Berry, C. (2021) Clinical significance of coronavirus disease 2019 in hospitalized patients with myocardial injury. Clinical Cardiology, 44(3), pp. 332-339. (doi: 10.1002/clc.23530) (PMID:33501708) (PMCID:PMC7943910)

Neves, K. B. , Morris, H., Alves-Lopes, R., Muir, K. W. , Moreton, F., Delles, C. , Montezano, A. C. and Touyz, R. M. (2021) Peripheral arteriopathy caused by Notch3 gain-of-function mutation involves ER and oxidative stress and blunting of NO∕sGC∕cGMP pathway. Clinical Science, 135(6), pp. 753-773. (doi: 10.1042/CS20201412) (PMID:33681964)

Main, A. and Fuller, W. (2021) Protein S‐palmitoylation: advances and challenges in studying a therapeutically important lipid modification. FEBS Journal, (doi: 10.1111/febs.15781) (Early Online Publication)

Docherty, K. F. et al. (2021) Effect of dapagliflozin on anaemia in DAPA-HF. European Journal of Heart Failure, (doi: 10.1002/ejhf.2132) (PMID:33615642) (Early Online Publication)

Ferreira, J. P. et al. (2021) Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial. European Journal of Heart Failure, (doi: 10.1002/ejhf.2134) (PMID:33609066) (Early Online Publication)

Ehteshami-Afshar, S. et al. (2021) Clinical characteristics and outcomes of patients with heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: insights from PARADIGM-HF. Journal of the American Heart Association, 10(4), e019238. (doi: 10.1161/JAHA.120.019238) (PMID:33522249) (PMCID:PMC7955331)

Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. European Journal of Heart Failure, (doi: 10.1002/ejhf.2124) (PMID:33594755) (In Press)

Lee, M. M.Y. et al. (2021) Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 143(6), pp. 516-525. (doi: 10.1161/CIRCULATIONAHA.120.052186) (PMID:33186500) (PMCID:PMC7864599)

Petrie, M. C. , Lee, M. M. and Lang, N. N. (2021) EMPEROR-REDUCED reigns while EMPERIAL whimpers. European Heart Journal, 42(6), pp. 711-714. (doi: 10.1093/eurheartj/ehaa965) (PMID:33367572)

Rankin, A. J. et al. (2021) Global longitudinal strain by feature tracking cardiovascular MRI predicts mortality in patients with end stage kidney disease. Clinical Kidney Journal, (doi: 10.1093/ckj/sfab020) (Early Online Publication)

Connelly, P. J. , Clark, A., Touyz, R. M. and Delles, C. (2021) Transgender adults, gender-affirming hormone therapy and blood pressure: a systematic review. Journal of Hypertension, 39(2), pp. 223-230. (doi: 10.1097/HJH.0000000000002632) (PMID:32809982) (PMCID:PMC7810409)

Docherty, K. F. et al. (2021) Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling. ESC Heart Failure, 8(1), pp. 129-138. (doi: 10.1002/ehf2.13137) (PMID:33305513) (PMCID:PMC7835504)

Hastie, C., Pell, J. and Sattar, N. (2021) Vitamin D and COVID-19 infection and mortality in UK Biobank. European Journal of Nutrition, 60, pp. 545-548. (doi: 10.1007/s00394-020-02372-4) (PMID:32851419) (PMCID:PMC7449523)

Maznyczka, A. M. et al. (2021) Risk stratification guided by the index of microcirculatory resistance and left ventricular end-diastolic pressure in acute myocardial infarction. Circulation: Cardiovascular Interventions, 14(2), e009529. (doi: 10.1161/CIRCINTERVENTIONS.120.009529) (PMID:33591821)

Maznyczka, A. M. et al. (2021) Effect of coronary flow on intracoronary alteplase: a prespecified analysis from a randomised trial. Heart, 107(4), pp. 299-312. (doi: 10.1136/heartjnl-2020-317828) (PMID:33436493)

Li, W., Gao, H. , Mangion, K., Berry, C. and Luo, X. (2021) Apparent growth tensor of left ventricular post myocardial infarction – in human first natural history study. Computers in Biology and Medicine, 129, 104168. (doi: 10.1016/j.compbiomed.2020.104168) (PMID:33341555)

Kuriakose, J., Montezano, A. C. and Touyz, R. M. (2021) ACE-2/Ang (1-7)/Mas axis and the vascular system: vasoprotection to COVID-19-associated vascular disease. Clinical Science, 135(2), pp. 387-407. (doi: 10.1042/CS20200480)

Petrie, M. C. , Lee, M. M.Y. and Docherty, K. F. (2021) SGLT2 inhibitors ‐ the first successful treatment for HFpEF? European Journal of Heart Failure, (doi: 10.1002/ejhf.2108) (PMID:33502794) (Early Online Publication)

Jhund, P. S. et al. (2021) Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. Circulation, 143(4), pp. 289-309. (doi: 10.1161/CIRCULATIONAHA.120.050391) (PMID:33040613) (PMCID:PMC7834909)

Willder, J. M., McCall, P. , Messow, C.-M. , Gillies, M., Berry, C. and Shelley, B. (2021) Study protocol for COVID-RV: a multicentre prospective observational cohort study of right ventricular dysfunction in ventilated patients with COVID-19. BMJ Open, 11(1), e042098. (doi: 10.1136/bmjopen-2020-042098) (PMID:33441361) (PMCID:PMC7811959)

Dobbin, S. J.H. , Petrie, M. C. , Myles, R. C. , Touyz, R. M. and Lang, N. N. (2021) Cardiotoxic effects of angiogenesis inhibitors. Clinical Science, 135(1), pp. 71-100. (doi: 10.1042/CS20200305) (PMID:33404052) (PMCID:PMC7812690)

McMurray, J. J.V. and Docherty, K. F. (2021) SOLOIST-WHF: Sodium-glucose cotransporter 2 (SGLT2) inhibitors should be initiated in patients hospitalised with worsening heart failure. European Journal of Heart Failure, 23(1), pp. 27-30. (doi: 10.1002/ejhf.2075) (PMID:33283384)

Boguslavskyi, A. et al. (2021) Phospholemman phosphorylation regulates vascular tone, blood pressure and hypertension in mice and man. Circulation, 143(11), pp. 1123-1138. (doi: 10.1161/CIRCULATIONAHA.119.040557) (PMID:33334125) (PMCID:PMC7969167)

Pellicori, P. et al. (2021) COVID-19 and its cardiovascular effects: a systematic review of prevalence studies. Cochrane Database of Systematic Reviews, 2021(3), CD013879. (doi: 10.1002/14651858.CD013879)

Lee, M. M.Y. et al. (2020) Renin–angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis. European Heart Journal: Cardiovascular Pharmacotherapy, (doi: 10.1093/ehjcvp/pvaa138) (PMID:33337478) (PMCID:PMC7799280) (Early Online Publication)

Murray, E. , Rossitto, G. and Delles, C. (2020) Haemodynamic assessment in hypertension: the soloists and the orchestra. Journal of Hypertension, (Accepted for Publication)

Dewan, P. et al. (2020) Effects of dapagliflozin in heart failure with reduced ejection fraction, and chronic obstructive pulmonary disease: an analysis of DAPA-HF. European Journal of Heart Failure, (doi: 10.1002/ejhf.2083) (PMID:33368858) (Early Online Publication)

Rossitto, G. et al. (2020) Reduced lymphatic reserve in heart failure with preserved ejection fraction. Journal of the American College of Cardiology, 76(24), pp. 2817-2829. (doi: 10.1016/j.jacc.2020.10.022)

Kristensen, S. L. et al. (2020) Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM‐HF and ATMOSPHERE. European Journal of Heart Failure, 22(12), pp. 2370-2379. (doi: 10.1002/ejhf.1972) (PMID:32720404)

Ferreira, J. P. et al. (2020) Estimating the lifetime benefits of treatments for heart failure. JACC: Heart Failure, 8(12), pp. 984-995. (doi: 10.1016/j.jchf.2020.08.004) (PMID:33039448) (PMCID:PMC7720789)

Pashova, A., Work, L.M. and Nicklin, S.A. (2020) The role of extracellular vesicles in neointima formation post vascular injury. Cellular Signalling, 76, 109783. (doi: 10.1016/j.cellsig.2020.109783) (PMID:32956789)

Main, A., Fuller, W. and Baillie, G. S. (2020) Post-translational regulation of cardiac myosin binding protein-C: a graphical review. Cellular Signalling, 76, 109788. (doi: 10.1016/j.cellsig.2020.109788) (PMID:32976931)

Ho, F. K. et al. (2020) Modifiable and non-modifiable risk factors for COVID-19, and comparison to risk factors for influenza and pneumonia: results from a UK Biobank prospective cohort study. BMJ Open, 10, e040402. (doi: 10.1136/bmjopen-2020-040402) (PMID:33444201) (PMCID:PMC7678347)

Dewan, P. et al. (2020) The prevalence and importance of frailty in heart failure with reduced ejection fraction – an analysis of PARADIGM-HF and ATMOSPHERE. European Journal of Heart Failure, 22(11), pp. 2123-2133. (doi: 10.1002/ejhf.1832) (PMID:32353205)

Morrow, A. J. et al. (2020) Rationale and design of the Medical Research Council precision medicine with Zibotentan in microvascular angina (PRIZE) trial. American Heart Journal, 229, pp. 70-80. (doi: 10.1016/j.ahj.2020.07.007) (PMID:32942043)

Charla, E., Mercer, J. , Maffia, P. and Nicklin, S. (2020) Extracellular vesicle signalling in atherosclerosis. Cellular Signalling, 75, 109751. (doi: 10.1016/j.cellsig.2020.109751) (PMID:32860954) (PMCID:PMC7534042)

Ferreira, J. P., Mogensen, U. M., Jhund, P. S. , Desai, A. S., Zile, M. R., Rossignol, P., Zannad, F., Packer, M., Solomon, S. D. and McMurray, J. J.V. (2020) Serum potassium in the PARADIGM-HF trial. European Journal of Heart Failure, 22(11), pp. 2056-2064. (doi: 10.1002/ejhf.1987) (PMID:32809261) (PMCID:PMC7756204)

Docherty, K. et al. (2020) Effect of dapagliflozin in DAPA-HF according to background glucose-lowering therapy. Diabetes Care, 43(11), pp. 2878-2881. (doi: 10.2337/dc20-1402) (PMID:33082245)

Docherty, K. F. et al. (2020) Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction: a prespecified analysis of DAPA-HF. Circulation, 142(17), pp. 1623-1632. (doi: 10.1161/CIRCULATIONAHA.120.047480) (PMID:32883108) (PMCID:PMC7580857)

Welsh, P. et al. (2020) Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction and estimating benefits from novel interventions. European Journal of Preventive Cardiology, (doi: 10.1093/eurjpc/zwaa063) (Early Online Publication)

Lang, N. N. , Dobbin, S. J.H. and Petrie, M. C. (2020) Vericiguat in worsening heart failure – agonising over, or celebrating, agonism. Cardiovascular Research, 116(12), e152-e155. (doi: 10.1093/cvr/cvaa247) (PMID:32980877)

Dewan, P. , Jhund, P. S. and McMurray, J. J.V. (2020) VICTORIA in context. European Journal of Heart Failure, 22(10), pp. 1747-1751. (doi: 10.1002/ejhf.1833) (PMID:32363731)

Martinez-Amezcua, P. et al. (2020) The upcoming epidemic of heart failure in South Asia. Circulation: Heart Failure, 13(10), e007218. (doi: 10.1161/CIRCHEARTFAILURE.120.007218) (PMID:32962410)

Serenelli, M. et al. (2020) Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). European Heart Journal, 41(36), pp. 3402-3418. (doi: 10.1093/eurheartj/ehaa496) (PMID:32820334) (PMCID:PMC7550197)

Jackson, A. M. et al. (2020) Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF. Circulation, 142(11), pp. 1040-1054. (doi: 10.1161/CIRCULATIONAHA.120.047077) (PMID:32673497) (PMCID:PMC7664959)

Cameron, A. C. et al. (2020) Comprehensive characterisation of the vascular effects of cisplatin-based chemotherapy in patients with testicular cancer. JACC: CardioOncology, 2(3), pp. 443-455. (doi: 10.1016/j.jaccao.2020.06.004) (PMID:33043304) (PMCID:PMC7539369)

Sattar, N. et al. (2020) BMI and future risk for COVID-19 infection and death across sex, age and ethnicity: preliminary findings from UK biobank. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 14(5), pp. 1149-1151. (doi: 10.1016/j.dsx.2020.06.060) (PMID:32668401) (PMCID:PMC7326434)

Ford, T. J. et al. (2020) Assessment of vascular dysfunction in patients without obstructive coronary artery disease: why, how and when. JACC: Cardiovascular Interventions, 13(16), pp. 1847-1864. (doi: 10.1016/j.jcin.2020.05.052) (PMID:32819476) (PMCID:PMC7447977)

Rossitto, G. et al. (2020) Tissue sodium excess is not hypertonic and reflects extracellular volume expansion. Nature Communications, 11, 4222. (doi: 10.1038/s41467-020-17820-2) (PMID:32839436) (PMCID:PMC7445299)

McClure, J. D. , Ramsay, J. C. and Berry, C. (2020) Pooled analysis of bleeding and major adverse cardiovascular events in clinical trials of time-constrained dual-antiplatelet therapy after percutaneous coronary intervention. Journal of the American Heart Association, 9(16), e017109. (doi: 10.1161/JAHA.120.017109) (PMID:32779497) (PMCID:PMC7660822)

Guzik, T. J. et al. (2020) COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovascular Research, 116(10), pp. 1666-1687. (doi: 10.1093/cvr/cvaa106) (PMID:32352535) (PMCID:PMC7197627)

Campbell, R. T. et al. (2020) The novel urinary proteomic classifier HF1 has similar diagnostic and prognostic utility to BNP in heart failure. ESC Heart Failure, 7(4), pp. 1595-1604. (doi: 10.1002/ehf2.12708) (PMID:32383555) (PMCID:PMC7373887)

Dobbie, L. J., Mackin, S. T., Hogarth, K., Lonergan, F., Kannenkeril, D., Brooksbank, K. and Delles, C. (2020) Validation of semi-automated flow mediated dilation measurement in healthy volunteers. Blood Pressure Monitoring, 25(4), pp. 216-223. (doi: 10.1097/MBP.0000000000000448) (PMID:32304385) (PMCID:PMC7331823)

Zou, Z.-G. et al. (2020) Epidermal growth factor signaling through transient receptor potential melastatin 7 cation channel regulates vascular smooth muscle cell function. Clinical Science, 134(15), pp. 2019-2035. (doi: 10.1042/CS20200827) (PMID:32706027)

Connelly, P. J. , Jandeleit-Dahm, K. A.M. and Delles, C. (2020) Sex and gender aspects in vascular pathophysiology. Clinical Science, 134(16), pp. 2203-2207. (doi: 10.1042/CS20200876) (PMID:32844996)

Pellicori, P. and Cleland, J. G.F. (2020) Structural heart disease, cardiac dysfunction and heart failure: the ambiguity of a definition. European Journal of Preventive Cardiology, (doi: 10.1177/2047487320937135) (PMID:32718235) (Early Online Publication)

Bulluck, H. et al. (2020) Redefining adverse and reverse left ventricular remodeling by cardiovascular magnetic resonance following ST-segment elevation myocardial infarction and their implications on long-term prognosis. Circulation: Cardiovascular Imaging, 13(7), e009937. (doi: 10.1161/CIRCIMAGING.119.009937) (PMID:32689822)

Fong, L. C. W., Ford, T. J. , da Costa, B. R., Jüni, P. and Berry, C. (2020) Bias and loss to follow-up in cardiovascular randomized trials: a systematic review. Journal of the American Heart Association, 9(14), e015361. (doi: 10.1161/JAHA.119.015361) (PMID:32646264) (PMCID:PMC7660731)

Louca, P., Mompeo, O., Leeming, E. R., Berry, S. E., Mangino, M., Spector, T. D., Padmanabhan, S. and Menni, C. (2020) Dietary influence on systolic and diastolic blood pressure in the TwinsUK cohort. Nutrients, 12(7), 2130. (doi: 10.3390/nu12072130) (PMID:32708992) (PMCID:PMC7400881)

Docherty, K. F. et al. (2020) Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. European Heart Journal, 41(25), pp. 2379-2392. (doi: 10.1093/eurheartj/ehaa183) (PMID:32221582) (PMCID:PMC7327533)

Dobbin, S. J.H. et al. (2020) Cardiotoxicity and myocardial hypoperfusion associated with anti-VEGF therapies: prospective cardiac magnetic resonance imaging in patients with cancer. European Journal of Heart Failure, 22(7), pp. 1276-1277. (doi: 10.1002/ejhf.1847) (PMID:32379945)

Hastie, C. E. et al. (2020) Vitamin D concentrations and COVID-19 infection in UK Biobank. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 14(4), pp. 561-565. (doi: 10.1016/j.dsx.2020.04.050) (PMID:32413819) (PMCID:PMC7204679)

Sattar, N. , McInnes, I. B. and McMurray, J. J.V. (2020) Obesity a risk factor for severe COVID-19 infection: multiple potential mechanisms. Circulation, 142(1), pp. 4-6. (doi: 10.1161/CIRCULATIONAHA.120.047659) (PMID:32320270)

Dewan, P. et al. (2020) Efficacy and safety of sodium–glucose co‐transporter 2 inhibition according to left ventricular ejection fraction in DAPA‐HF. European Journal of Heart Failure, 22(7), pp. 1247-1258. (doi: 10.1002/ejhf.1867) (PMID:32539224)

Cleland, J. G.F. , Li, C. and Jones, Y. (2020) Artificial intelligence needs clinical intelligence to succeed. JACC: Heart Failure, 8(7), pp. 588-591. (doi: 10.1016/j.jchf.2020.06.002) (PMID:32616167)

Gök, C. , Plain, F., Robertson, A., Howie, J., Baillie, G. S. , Fraser, N. J. and Fuller, W. (2020) Dynamic palmitoylation of the sodium-calcium exchanger modulates its structure, affinity for lipid ordered domains, and inhibition by XIP. Cell Reports, 31(10), 107697. (doi: 10.1016/j.celrep.2020.107697) (PMID:32521252) (PMCID:PMC7296346)

Picone, D. S. et al. (2020) Nonvalidated home blood pressure devices dominate the online marketplace in Australia: major implications for cardiovascular risk management. Hypertension, 75(6), pp. 1593-1599. (doi: 10.1161/hypertensionaha.120.14719) (PMID:32275193)

Touyz, R. M. , Feldman, R. D., Harrison, D. G. and Schiffrin, E. L. (2020) A new look at the mosaic theory of hypertension. Canadian Journal of Cardiology, 36(5), pp. 591-592. (doi: 10.1016/j.cjca.2020.03.025) (PMID:32389334)

Lip, S. and Padmanabhan, S. (2020) Genomics of blood pressure and hypertension: extending the mosaic theory toward stratification. Canadian Journal of Cardiology, 36(5), pp. 694-705. (doi: 10.1016/j.cjca.2020.03.001) (PMID:32389342) (PMCID:PMC7237883)

Delles, C. and Olfert, M. (2020) Electronic cigarettes: how bad are they for your health? Cardiovascular Research, 116(6), e64-e66. (doi: 10.1093/cvr/cvaa041) (PMID:32157289)

Touyz, R. , Rios, F. , Alves-Lopes, R., Neves, K. B. , De Lucca Camargo, L. and Montezano, A. C. (2020) Oxidative stress: a unifying paradigm in hypertension. Canadian Journal of Cardiology, 36, pp. 659-670. (doi: 10.1016/j.cjca.2020.02.081) (PMID:32389339) (PMCID:PMC7225748)

Maznyczka, A. M. et al. (2020) Comparative significance of invasive measures of microvascular injury in acute myocardial infarction. Circulation: Cardiovascular Interventions, 13(5), e008505. (doi: 10.1161/CIRCINTERVENTIONS.119.008505) (PMID:32408817) (PMCID:PMC7237023)

Petrie, M. C., et al. (2020) Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA: Journal of the American Medical Association, 323(14), pp. 1353-1368. (doi: 10.1001/jama.2020.1906) (PMID:32219386) (PMCID:PMC7157181)

Delles, C. , Li, H. and Touyz, R. M. (2020) ACE2 the Janus-faced protein – from cardiovascular protection to severe acute respiratory syndrome-coronavirus and COVID-19. Clinical Science, 134(7), pp. 747-750. (doi: 10.1042/CS20200363)

Cleland, J. G.F. , Lyon, A. R., McDonagh, T. and McMurray, J. J.V. (2020) The year in cardiology: heart failure. European Heart Journal, 41(12), pp. 1232-1248. (doi: 10.1093/eurheartj/ehz949) (PMID:31901936) (PMCID:PMC7084174)

Berry, C. and Duncker, D. J. (2020) Coronary microvascular disease: the next frontier for Cardiovascular Research. Cardiovascular Research, 116(4), pp. 737-740. (doi: 10.1093/cvr/cvaa035) (PMID:32149331) (PMCID:PMC7061275)

Maznyczka, A. M. et al. (2020) Thermodilution-derived temperature recovery time, a novel predictor of microvascular reperfusion and prognosis after myocardial infarction. EuroIntervention, (PMID:32122822) (Early Online Publication)

Sattar, N. , Gill, J. M.R. and Alazawi, W. (2020) Improving prevention strategies for cardiometabolic disease. Nature Medicine, 26(3), pp. 320-325. (doi: 10.1038/s41591-020-0786-7) (PMID:32152584)

Serenelli, M. et al. (2020) Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart failure with reduced ejection fraction. JACC: Heart Failure, 8(3), pp. 188-198. (doi: 10.1016/j.jchf.2019.09.011) (PMID:31926854) (PMCID:PMC7086149)

Rorth, R. et al. (2020) Comparison of BNP and NT-proBNP in patients with heart failure and reduced ejection fraction. Circulation: Heart Failure, 13(2), e006541. (doi: 10.1161/CIRCHEARTFAILURE.119.006541) (PMID:32065760)

McMurray, J. J.V. et al. (2020) Effects of Sacubitril-Valsartan, versus Valsartan, in Women Compared to Men with Heart Failure and Preserved Ejection Fraction: Insights from PARAGON-HF. Circulation, 141(5), pp. 338-351. (doi: 10.1161/CIRCULATIONAHA.119.044491) (PMID:31736337)

Crouch, S. H., Botha-Le Roux, S., Delles, C. , Graham, L. A. and Schutte, A. E. (2020) Distinct inflammatory mediator patterns in young black and white adults: The African-PREDICT study. Cytokine, 126, 154894. (doi: 10.1016/j.cyto.2019.154894)

Maznyczka, A. M. et al. (2020) One-year outcomes after low-dose intracoronary alteplase during primary percutaneous coronary intervention. The T-TIME randomized trial. Circulation: Cardiovascular Interventions, 13(2), e008855. (doi: 10.1161/CIRCINTERVENTIONS.119.008855) (PMID:32069113)

Welsh, C. et al. (2020) Glycated hemoglobin, prediabetes and the links to cardiovascular disease: data from UK Biobank. Diabetes Care, 43(2), pp. 440-445. (doi: 10.2337/dc19-1683) (PMID:31852727)

Martinez, F. A. et al. (2020) Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF. Circulation, 141(2), pp. 100-111. (doi: 10.1161/CIRCULATIONAHA.119.044133) (PMID:31736328)

Chapman, A. R. et al. (2020) High-sensitivity cardiac troponin and the universal definition of myocardial infarction. Circulation, 141(3), pp. 161-171. (doi: 10.1161/CIRCULATIONAHA.119.042960) (PMID:31587565) (PMCID:PMC6970546)

Coll, A. P. et al. (2020) GDF15 mediates the effects of metformin on body weight and energy balance. Nature, 578, pp. 444-448. (doi: 10.1038/s41586-019-1911-y) (PMID:31875646) (PMCID:PMC7234839)

Robertson, J., Lindgren, M., Schaufelberger, M., Adiels, M., Björck, L., Lundberg, C. E., Sattar, N. , Rosengren, A. and Åberg, M. (2020) Body Mass Index in young women and risk of cardiomyopathy: a long-term follow-up study in Sweden. Circulation, 141(7), pp. 520-529. (doi: 10.1161/CIRCULATIONAHA.119.044056) (PMID:32065765) (PMCID:PMC7017947)

Kotecha, D. et al. (2019) Impact of renal impairment on beta-blocker efficacy in patients with heart failure. Journal of the American College of Cardiology, 74(23), pp. 2893-2904. (doi: 10.1016/j.jacc.2019.09.059) (PMID:31806133)

Dewan, P. et al. (2019) Sex-related differences in heart failure with preserved ejection fraction. Circulation: Heart Failure, 12(12), e006539. (doi: 10.1161/CIRCHEARTFAILURE.119.006539) (PMID:31813280)

Neves, K. B. et al. (2019) ER stress and Rho kinase activation underlie the vasculopathy of CADASIL. JCI Insight, 4(23), e131344. (doi: 10.1172/jci.insight.131344) (PMID:31647781) (PMCID:PMC6962020)

Cameron, A. C. et al. (2019) Progressive hypertension and severe left ventricular outflow tract obstruction. Hypertension, 74(6), pp. 1216-1225. (doi: 10.1161/hypertensionaha.119.13343) (PMID:31587571)

Kristensen, S. L., Rorth, R., Jhund, P. S. , Docherty, K. , Sattar, N. , Preiss, D. , Kober, L., Petrie, M. C. and McMurray, J. J.V. (2019) Cardiovascular, mortality and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes and Endocrinology, 7(10), pp. 776-785. (doi: 10.1016/S2213-8587(19)30249-9) (PMID:31422062)

Shen, L. et al. (2019) Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. European Journal of Heart Failure, 21(8), pp. 974-984. (doi: 10.1002/ejhf.1535) (PMID:31271255) (PMCID:PMC7079555)

Maznyczka, A. M., Oldroyd, K. G., McCartney, P., McEntegart, M. and Berry, C. (2019) The potential use of the index of microcirculatory resistance to guide stratification of patients for adjunctive therapy in acute myocardial infarction. JACC: Cardiovascular Interventions, 12(10), pp. 951-966. (doi: 10.1016/j.jcin.2019.01.246) (PMID:31122353)

This list was generated on Sun May 16 10:56:26 2021 BST.